StreetInsider.com News Articles

Form 8-K Traws Pharma, Inc. For: Feb 19

Thu, 19 Feb 2026 08:43:00 -0500

si-local-file:///var/storage/secattach/20260219/26026746.html

Form 8-K Traws Pharma, Inc. For: Feb 19

Thu, 19 Feb 2026 08:43:00 -0500

si-local-file:///var/storage/secattach/20260219/26026746.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ikarian Capital, LLC

Tue, 17 Feb 2026 17:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26015034.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ikarian Capital, LLC

Tue, 17 Feb 2026 17:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26015034.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Squadron Capital Management LLC

Tue, 17 Feb 2026 12:36:00 -0500

si-local-file:///var/storage/secattach/20260217/26010203.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Squadron Capital Management LLC

Tue, 17 Feb 2026 12:36:00 -0500

si-local-file:///var/storage/secattach/20260217/26010203.html

Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.

Thu, 12 Feb 2026 09:11:00 -0500

si-local-file:///var/storage/secattach/20260212/25988568.html

Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.

Thu, 12 Feb 2026 09:11:00 -0500

si-local-file:///var/storage/secattach/20260212/25988568.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ayrton Capital LLC

Wed, 11 Feb 2026 09:44:00 -0500

si-local-file:///var/storage/secattach/20260211/25980838.html

Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ayrton Capital LLC

Wed, 11 Feb 2026 09:44:00 -0500

si-local-file:///var/storage/secattach/20260211/25980838.html

Ladenburg Thalmann Starts Traws Pharma Inc. (TRAW) at Buy

Fri, 30 Jan 2026 06:42:45 -0500

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Traws Pharma Inc. (NASDAQ: TRAW) with a Buy rating and a price target of $6.50.

For an analyst ratings summary and ratings history on Traws Pharma Inc. click here. For more ratings news on Traws Pharma Inc. click here.

Shares of Traws Pharma Inc. closed at $2.10 yesterday.

Traws Pharma completes enrollment in COVID-19 drug study

Mon, 26 Jan 2026 08:32:34 -0500

Traws Pharma Inc. (NASDAQ: TRAW) completed enrollment in its 90-patient Phase 2 study comparing ratutrelvir to Paxlovid in patients with mild-to-moderate COVID-19. The study included patients eligible for Paxlovid treatment and a separate arm for those ineligible for ritonavir-based therapies due to contraindications or drug interactions.

The study evaluated ratutrelvir 600 mg taken once daily for 10 days against Paxlovid administered twice daily for 5 days. According to the company, ongoing data analysis shows ratutrelvir patients experienced fewer adverse events, no viral rebounds, and faster symptom resolution compared to Paxlovid patients.

"The favorable tolerability profile, together with a shortened time to symptom

Traws Pharma completes enrollment in COVID-19 drug study

Mon, 26 Jan 2026 08:32:34 -0500

"The favorable tolerability profile, together with a shortened time to symptom

Form 8-K Traws Pharma, Inc. For: Jan 26

Mon, 26 Jan 2026 08:31:00 -0500

si-local-file:///var/storage/secattach/20260126/25890751.html

Form 8-K Traws Pharma, Inc. For: Jan 26

Mon, 26 Jan 2026 08:31:00 -0500

si-local-file:///var/storage/secattach/20260126/25890751.html

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic T

Mon, 26 Jan 2026 08:30:00 -0500

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID^® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID^®-ineligible patients, representing a significant population with few effective treatment options

Compressed tablets of tivoxavir marboxil predicted to provide 28-day protection from influenza against wide range of seasonal and pandemic-potential variants

Human influenza prophylaxis challenge study time slot secured for June 2026

NEWTOWN, Pa., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”,

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic T

Mon, 26 Jan 2026 08:30:00 -0500

Compressed tablets of tivoxavir marboxil predicted to provide 28-day protection from influenza against wide range of seasonal and pandemic-potential variants

Human influenza prophylaxis challenge study time slot secured for June 2026

NEWTOWN, Pa., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”,

Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Chernett Jorey

Fri, 16 Jan 2026 16:48:00 -0500

si-local-file:///var/storage/secattach/20260116/25860938.html

Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Chernett Jorey

Fri, 16 Jan 2026 16:48:00 -0500

si-local-file:///var/storage/secattach/20260116/25860938.html

Traws Pharma files IND application for influenza drug tivoxavir marboxil

Tue, 13 Jan 2026 07:03:28 -0500

Traws Pharma Inc. (NASDAQ: TRAW) filed an Investigational New Drug application with the U.S. Food and Drug Administration for tivoxavir marboxil, an oral tablet treatment for influenza. The filing represents a step toward potential consideration by the Center for the Biomedical Advanced Research and Development Authority for inclusion in the strategic national stockpile.

The company also released updated interim results from its ongoing Phase 2 study of ratutrelvir, a COVID-19 treatment. The randomized, open-label study compared ratutrelvir against Paxlovid in patients with mild-to-moderate COVID-19, with a separate arm for patients ineligible for Paxlovid treatment.

The interim analysis included 50 patients, with 32

Traws Pharma files IND application for influenza drug tivoxavir marboxil

Tue, 13 Jan 2026 07:03:28 -0500

The interim analysis included 50 patients, with 32

Form 8-K Traws Pharma, Inc. For: Jan 13

Tue, 13 Jan 2026 07:01:00 -0500

si-local-file:///var/storage/secattach/20260113/25840468.html

Form 8-K Traws Pharma, Inc. For: Jan 13

Tue, 13 Jan 2026 07:01:00 -0500

si-local-file:///var/storage/secattach/20260113/25840468.html

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligib

Tue, 13 Jan 2026 07:00:00 -0500

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile

Updated clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID^® with fewer adverse events, no viral rebounds and faster time to sustained symptom resolution

Ratutrelvir’s safety and efficacy advantage recapitulated in PAXLOVID^®-ineligible patients, representing a significant population with few effective treatment options